Covered recipient · General Payments record
SEREN DURER
General Payments · PY2022–2024
$739.82
- Reported across 30 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $212.50 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $52.78 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $48.63 | 2 |
| Celgene Corporation | $33.19 | 2 |
| Daiichi Sankyo Inc. | $22.35 | 1 |
| Acerta Pharma LLC | $20.36 | 1 |
| PFIZER INC. | $19.86 | 1 |
| ADC Therapeutics America, Inc. | $15.33 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.94 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103669610 | CMS |
| ABBVIE INC. | $30.84 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103669612 | CMS |
| ADC Therapeutics America, Inc. | $15.33 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1121190985 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.36 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110511222 | CMS |
| Celgene Corporation | $15.32 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101108280 | CMS |
| Celgene Corporation | $17.87 | 08/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101108286 | CMS |
| Daiichi Sankyo Inc. | $22.35 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089417762 | CMS |
| PFIZER INC. | $19.86 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131310308 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.06 | 01/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144956891 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $30.57 | 04/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144956893 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.